With 450 attorneys and government relations professionals across 15 offices, Buchanan Ingersoll & Rooney provides progressive legal, business, regulatory and government relations advice to protect, defend and advance our clients’ businesses. We service a wide range of clients, with deep experience in the finance, energy, healthcare and life sciences industries.
To print this article, all you need is to be registered or login on Mondaq.com.
Edward John Allera, co-chair of the firm's FDA group,
and Matthew Fedowitz, shareholder in the firm's
Intellectual Property section, will present Key Business and IP
Considerations for Furthering Drug Repurposing Programs for
the 9th Annual Repositioning, Repurposing and Rescue
Conference.
The presentation will cover the following:
Increasing the value of your 505(b)(2)
Dealing with CMS actions that increase the value of independent
505(b)(2)s
Monitoring FDA and Congress for the impact of user fees on
505(b)(2)s
Assessing the impact of Executive Orders on 505(b)2()s
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
